Literature DB >> 24216478

Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Jaba Gamrekelashvili, Tamar Kapanadze, Miaojun Han, Josef Wissing, Chi Ma, Lothar Jaensch, Michael P Manns, Todd Armstrong, Elizabeth Jaffee, Ayla O White, Deborah E Citrin, Firouzeh Korangy, Tim F Greten.   

Abstract

Cross-priming of CD8+ T cells and generation of effector immune responses is pivotal for tumor immunity as well as for successful anticancer vaccination and therapy. Dead and dying cells produce signals that can influence Ag processing and presentation; however, there is conflicting evidence regarding the immunogenicity of necrotic cell death. We used a mouse model of sterile necrosis, in which mice were injected with sterile primary necrotic cells, to investigate a role of these cells in priming of CD8+ T cells. We discovered a molecular mechanism operating in Ag donor cells that regulates cross-priming of CD8+ T cells during primary sterile necrosis and thereby controls adaptive immune responses. We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase 1 (TOP-1), both of which are present in nonimmunogenic necrotic cells, eliminated proteasomal degradation products and blocked Ag cross-presentation. While sterile necrotic tumor cells failed to induce CD8+ T cell responses, their nonimmunogenicity could be reversed in vitro and in vivo by inactivation of DPP-3 and TOP-1. These results indicate that control of cross-priming and thereby immunogenicity of primary sterile necrosis relies on proteasome-dependent oligopeptide generation and functional status of peptidases in Ag donor cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24216478      PMCID: PMC3809774          DOI: 10.1172/JCI65698

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

1.  A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation.

Authors:  Eric Reits; Joost Neijssen; Carla Herberts; Willemien Benckhuijsen; Lennert Janssen; Jan Wouter Drijfhout; Jacques Neefjes
Journal:  Immunity       Date:  2004-04       Impact factor: 31.745

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

3.  Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.

Authors:  Wei-Chen Lee; Hui-Chuan Wang; Chien-Fu Hung; Pei-Fang Huang; Chen-Rong Lia; Miin-Fu Chen
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

4.  Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway.

Authors:  Edith Janssen; Koichi Tabeta; Michael J Barnes; Sophie Rutschmann; Sara McBride; Keith S Bahjat; Stephen P Schoenberger; Argyrios N Theofilopoulos; Bruce Beutler; Kasper Hoebe
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

5.  Thimet oligopeptidase and oligopeptidase M or neurolysin.

Authors:  A J Barrett; M A Brown; P M Dando; C G Knight; N McKie; N D Rawlings; A Serizawa
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

6.  Hyperthermia enhances CTL cross-priming.

Authors:  Hongzhen Shi; Tinghua Cao; John E Connolly; Laurence Monnet; Lynda Bennett; Sylvie Chapel; Claude Bagnis; Patrice Mannoni; Jean Davoust; A Karolina Palucka; Jacques Banchereau
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

7.  Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.

Authors:  Jan H Kessler; Selina Khan; Ulrike Seifert; Sylvie Le Gall; K Martin Chow; Annette Paschen; Sandra A Bres-Vloemans; Arnoud de Ru; Nadine van Montfoort; Kees L M C Franken; Willemien E Benckhuijsen; Jill M Brooks; Thorbald van Hall; Kallol Ray; Arend Mulder; Ilias I N Doxiadis; Paul F van Swieten; Hermen S Overkleeft; Annik Prat; Birgitta Tomkinson; Jacques Neefjes; Peter M Kloetzel; David W Rodgers; Louis B Hersh; Jan W Drijfhout; Peter A van Veelen; Ferry Ossendorp; Cornelis J M Melief
Journal:  Nat Immunol       Date:  2010-12-12       Impact factor: 25.606

8.  Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway.

Authors:  Jun Kunisawa; Nilabh Shastri
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

9.  The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation.

Authors:  Ian A York; Annie X Y Mo; Kristen Lemerise; Wanyong Zeng; Yuelei Shen; Carmela R Abraham; Tomo Saric; Alfred L Goldberg; Kenneth L Rock
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

10.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  15 in total

1.  Absence of Dipeptidyl Peptidase 3 Increases Oxidative Stress and Causes Bone Loss.

Authors:  Ciro Menale; Lisa J Robinson; Eleonora Palagano; Rosita Rigoni; Marco Erreni; Alejandro J Almarza; Dario Strina; Stefano Mantero; Michela Lizier; Antonella Forlino; Roberta Besio; Marta Monari; Paolo Vezzoni; Barbara Cassani; Harry C Blair; Anna Villa; Cristina Sobacchi
Journal:  J Bone Miner Res       Date:  2019-09-09       Impact factor: 6.741

Review 2.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 3.  Dying cells actively regulate adaptive immune responses.

Authors:  Nader Yatim; Sean Cullen; Matthew L Albert
Journal:  Nat Rev Immunol       Date:  2017-03-13       Impact factor: 53.106

Review 4.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 5.  Immunogenicity of necrotic cell death.

Authors:  Jaba Gamrekelashvili; Tim F Greten; Firouzeh Korangy
Journal:  Cell Mol Life Sci       Date:  2014-10-02       Impact factor: 9.261

Review 6.  Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.

Authors:  Matthew R Woeste; Anne E Geller; Robert C G Martin; Hiram C Polk
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

7.  RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells.

Authors:  Nader Yatim; Hélène Jusforgues-Saklani; Susana Orozco; Oliver Schulz; Rosa Barreira da Silva; Caetano Reis e Sousa; Douglas R Green; Andrew Oberst; Matthew L Albert
Journal:  Science       Date:  2015-09-24       Impact factor: 47.728

Review 8.  Boosting Tumor-Specific Immunity Using PDT.

Authors:  Nicole Maeding; Thomas Verwanger; Barbara Krammer
Journal:  Cancers (Basel)       Date:  2016-10-06       Impact factor: 6.639

9.  Combination surgery for hepatocellular carcinoma: slashing and burning to improved survival.

Authors:  John C McVey; Kazunari Sasaki
Journal:  Ann Transl Med       Date:  2020-08

Review 10.  Oncolytic viruses as anticancer vaccines.

Authors:  Norman Woller; Engin Gürlevik; Cristina-Ileana Ureche; Anja Schumacher; Florian Kühnel
Journal:  Front Oncol       Date:  2014-07-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.